Catalyst
Slingshot members are tracking this event:
FDA Grants Priority Review to Merck’s (MRK) Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Supplemental Biologics License Application, Keytruda, Pembrolizumab, New Indication In Microsatellite Instability-
